Clinical application of brain perfusion SPECT/CT imaging with NeuroGamTM software in subjective cognitive decline, mild cognitive impairment and Alzheimer's disease

BackgroundSubjective cognitive decline (SCD) and mild cognitive impairment (MCI) are a transitional state between normal aging and mild dementia, and most of them have potential Alzheimer's Disease (AD) pathology. Studying the pathophysiological characteristics of SCD and MCI is helpful to the early diagnosis of AD.PurposeThis study aims to investigate the brain perfusion differences among SCD, MCI and AD, and to evaluate the application value of brain perfusion SPECT/CT imaging combined with NeuroGamTM software in these diseases.MethodsFrom July 2020 to April 2021, 15 patients with SCD, 29 patients with MCI and 36 patients with AD were collected from several general hospitals in Shanghai. All subjects underwent neuropsychological test and 99mTc-ECD brain perfusion SPECT/CT imaging. The perfusion levels of Brodmann areas (BA) in the three groups were semi-quantitatively analyzed by NeuroGamTM, and compared with normal database. Student's t-test, one-way analysis of variance and rank sum test were used for the